What In The World Is Going On With Panbela Therapeutics (PBLA) Stock?

Panbela Therapeutics Inc PBLA shares are trading higher by 62% to $1.64 during Tuesday's session on upward momentum. The move comes after the company on Monday announced FDA approval of eflornithine, a drug they divested to US WorldMeds, for treating high-risk neuroblastoma patients who responded partially to prior therapies.

Panbela Therapeutics on Monday announced the first FDA approval for a polyamine targeted therapy in cancer, potentially receiving up to $9.5 million based on USWM milestones. The company said this underscores the significance of polyamines in cancer therapy.

Company executives expressed optimism about its impact on neuroblastoma treatment and potential implications for other cancers under investigation.

See Also: Why ETAO International Stock Is Down 39%

According to data from Benzinga Pro, PBLA has a 52-week high of $225.71 and a 52-week low of $0.45.